About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

95.89 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
News headline image
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
From Adagene Inc.
Via GlobeNewswire
News headline image
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte (NASDAQ:INCY) and its peers. The bio... 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Incyte Corp (NASDAQ:INCY) Presents a Compelling Value Case with Strong Fundamentals ↗
Via Chartmill
Incyte Corp. (NASDAQ:INCY) Reports Mixed Q4 2025 Results with Revenue Beat and EPS Miss ↗
Via Chartmill
News headline image
Incyte Announces Executive Leadership Appointments
From Incyte
Via Business Wire
News headline image
2 Growth Stocks with Explosive Upside and 1 We Avoid
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
News headline image
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
News headline image
1 Cash-Heavy Stock to Target This Week and 2 Facing Headwinds
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
Via StockStory
News headline image
2 Value Stocks to Consider Right Now and 1 We Ignore
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the... 
Via StockStory
News headline image
Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings?
Over the past six months, Incyte has been a great trade, beating the S&P 500 by 8.1%. Its stock price has climbed to $95.88, representing a healthy 11.3% inc... 
Via StockStory
Topics Stocks
News headline image
Incyte’s Drug Approved In Europe For Treating Yet Another Rare Cancer ↗
The company said that EC approved Zynyz in combination with carboplatin and paclitaxel for adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal... 
Via Stocktwits
News headline image
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
From Incyte
Via Business Wire
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Avoid
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
3 S&P 500 Stocks to Target This Week
The S&P 500 (^GSPC) is full of established businesses, but only some continue to outperform the market. A few standout companies are thriving thanks to strong fundamentals and sustained competitive... 
Via StockStory
Topics Stocks
News headline image
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Question
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps... 
Via StockStory
News headline image
Registration Momentum Builds Across the Oncology Pipeline
Issued on behalf of Oncolytics Biotech Inc. 
From USA News Group
Via GlobeNewswire
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
The Top 5 Analyst Questions From Incyte’s Q4 Earnings Call
Incyte’s fourth quarter was met with a negative market reaction, despite the company delivering revenue growth above Wall Street expectations. Management attributed this performance to strong... 
Via StockStory
Topics Earnings
News headline image
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q4 CY2025, with sales up 27.8% year on year to $1.51 billion. Its non-GAAP profit of $1.80 per share... 
Via StockStory
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Stay informed with the top movers within the S&P500 index on Tuesday. ↗
Via Chartmill
News headline image
Why Incyte (INCY) Stock Is Nosediving
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 8.8% in the morning session after the company reported mixed fourth-quarter 2025 results, where a significant revenue beat was... 
Via StockStory
Topics Artificial Intelligence Earnings
Which S&P500 stocks are gapping on Tuesday? ↗
Via Chartmill
News headline image
Incyte (INCY) Q4 2025 Earnings Call Transcript ↗
Incyte (INCY) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Which S&P500 stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.